SCHEMBL21591759

SCHEMBL21591759

NCc1ccc(Oc2ccnc3[nH]cc(-c4ccnc(NCc5ccccc5)c4)c23)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 5/20 0.44
PIM1 P11309 4/20 0.44
DYRK2 Q92630 2/20 0.44
DYRK1B Q9Y463 2/20 0.44
AAK1 Q2M2I8 1/20 0.43
CDC7 O00311 4/20 0.42
ROCK2 O75116 4/20 0.42
PRKACA P17612 3/20 0.42
CDK2 P24941 3/20 0.42
FLT3 P36888 3/20 0.42
GSK3B P49841 3/20 0.42
JAK3 P52333 3/20 0.42
HIPK2 Q9H2X6 3/20 0.42
ROCK1 Q13464 3/20 0.42
MAPK1 P28482 3/20 0.42
PLK4 O00444 2/20 0.42
CHEK1 O14757 2/20 0.42
JAK2 O60674 2/20 0.42
EGFR P00533 2/20 0.42
CSF1R P07333 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29836588 1.00 DYRK1A (0.44) DYRK1APIM1DYRK2DYRK1BAAK1
SCHEMBL29836539 0.87 MET (0.44) DYRK1APIM1DYRK2DYRK1BAAK1
SCHEMBL21591789 0.87 MET (0.44) DYRK1APIM1DYRK2DYRK1BAAK1
SCHEMBL21593178 0.83 CDC7 (0.41) DYRK1APIM1DYRK2DYRK1BAAK1
SCHEMBL29836518 0.83 CDC7 (0.41) DYRK1APIM1DYRK2DYRK1BAAK1
SCHEMBL21591777 0.83 IGF1R (0.47) DYRK1APIM1DYRK2DYRK1BJAK3
SCHEMBL29836484 0.83 IGF1R (0.47) DYRK1APIM1DYRK2DYRK1BJAK3
SCHEMBL23762196 0.81 CDC7 (0.38) DYRK1APIM1DYRK2DYRK1BAAK1
SCHEMBL21593087 0.79 MET (0.41) DYRK1APIM1CDC7ROCK2PRKACA
SCHEMBL29836476 0.79 MET (0.41) DYRK1APIM1CDC7ROCK2PRKACA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3807273-B1 AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS CHIESI FARM SPA (IT) 2022-08-03 EP claimed
US-20210253568-A1 AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2021-08-19 US claimed
EP-3807273-A1 AZAINDOLE DERIVATIVES AS RHO- KINASE INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2021-04-21 EP claimed
WO-2019238628-A1 AZAINDOLE DERIVATIVES AS RHO- KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2019-12-19 WO claimed
EP-3807273-B1 AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS CHIESI FARM SPA (IT) 2022-08-03 EP disclosed
US-20210253568-A1 AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2021-08-19 US disclosed
US-20210253568-A1 AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2021-08-19 US disclosed
WO-2019238628-A1 AZAINDOLE DERIVATIVES AS RHO- KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2019-12-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210253568-A1 AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS ROCK1, ROCK2, RHOA DYRK1A 1692/4885PIM1 1177/4885DYRK2 1350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.